StuffThatWorks Ltd.

StuffThatWorks Ltd. is a health-tech company that empowers patients by utilizing artificial intelligence to crowdsource treatment efficacy data for chronic conditions, enhancing patient engagement and informing healthcare practices. StuffThatWorks Ltd. was founded in 2018, based in Tel Aviv-Yafo, Israel.

The company specializes in creating a crowdsourcing platform for patients to share their experiences regarding chronic condition treatments. Sandra Sanders founded the company, leveraging her expertise in health technology. In July 2020, StuffThatWorks raised USD 9. 00 mn in SEED funding from investors including 83 North, Bessemer Venture Partners, and Galil Ofek Ventures, bringing the total amount raised to USD 9.

00 mn. StuffThatWorks is focused on empowering patients through an innovative crowdsourcing platform that identifies effective treatments for chronic conditions. The platform aggregates data using artificial intelligence, allowing users to share their experiences on treatment efficacy. This information creates a comprehensive knowledge base accessible to patients and healthcare providers, enhancing patient outcomes.

StuffThatWorks serves users in North America and Europe, including chronic illness patients, healthcare professionals, and researchers interested in patient-reported outcomes. The revenue model for StuffThatWorks is based on a subscription structure that invites users to contribute their experiences in exchange for access to valuable treatment data. The company may form partnerships with healthcare providers and pharmaceutical companies interested in aggregated patient data for research and development. Furthermore, it likely engages in direct-to-consumer transactions with tiered membership plans offering varying levels of access to features or exclusive content, although specific pricing details have not been disclosed.

The platform emphasizes a user-friendly interface that promotes active participation in chronic disease management. StuffThatWorks plans to utilize its recent funding of USD 9. 00 mn from the SEED round to enhance its platform offerings and engage a wider audience. While specific upcoming products have not been detailed, the company aims to expand its reach into additional North American and European markets, capitalizing on its existing user base.

The funding will support initiatives geared toward improving data aggregation capabilities and increasing user engagement, ultimately aiming for a broader impact on chronic disease management.